Chemotherapy for non-small cell lung cancer in elderly patients

Yuh Min Chen, Reury Perng Perng, Jen Fu Shih, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Study objective: To determine the appropriate chemotherapy regimen for inoperable, chemotherapy-naïve non-small cell lung cancer (NSCLC) in elderly patients. Setting: National teaching hospital in Taiwan. Design: We retrospectively analyzed data from our clinical trials for a total of 270 patients and compared them with the data from other studies, addressing the elderly in particular or providing subgroup information on age, to analyze the feasibility of current chemotherapy options for elderly patients and possible alternative approaches. Results: The response rates and median survival times of fit elderly patients with NSCLC who were receiving appropriate new anticancer drugs for chemotherapy, including single-agent or combination treatment, were no worse than those of younger patients, and the response rates may have been even higher in the elderly patients, while survival time was slightly poorer in this group. The risk of adverse side effects, such as myelosuppression and peripheral neuropathy, may be higher in elderly patients, who also visit the hospital more frequently. Some items on the lung cancer symptom scale for elderly patients were rated as being slightly worse than those for younger patients after chemotherapy. Conclusion: Advanced age alone should not preclude chemotherapy. New single-agent drugs, and non-platinum-based or platinum-based doublets, can all be considered as appropriate treatment for selected fit elderly patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalChest
Volume128
Issue number1
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Peripheral Nervous System Diseases
Platinum
Taiwan
Teaching Hospitals
Pharmaceutical Preparations
Lung Neoplasms
Survival Rate
Clinical Trials
Survival
Therapeutics

Keywords

  • Elderly
  • Gemcitabine
  • Non-small cell lung cancer
  • Taxane
  • Vinorelbine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Chemotherapy for non-small cell lung cancer in elderly patients. / Chen, Yuh Min; Perng, Reury Perng; Shih, Jen Fu; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: Chest, Vol. 128, No. 1, 01.01.2005, p. 132-139.

Research output: Contribution to journalArticle

Chen, YM, Perng, RP, Shih, JF, Tsai, CM & Whang-Peng, J 2005, 'Chemotherapy for non-small cell lung cancer in elderly patients', Chest, vol. 128, no. 1, pp. 132-139. https://doi.org/10.1378/chest.128.1.132
Chen, Yuh Min ; Perng, Reury Perng ; Shih, Jen Fu ; Tsai, Chun Ming ; Whang-Peng, Jacqueline. / Chemotherapy for non-small cell lung cancer in elderly patients. In: Chest. 2005 ; Vol. 128, No. 1. pp. 132-139.
@article{067e5c31ee8d4a04be5bae8d1260c743,
title = "Chemotherapy for non-small cell lung cancer in elderly patients",
abstract = "Study objective: To determine the appropriate chemotherapy regimen for inoperable, chemotherapy-na{\"i}ve non-small cell lung cancer (NSCLC) in elderly patients. Setting: National teaching hospital in Taiwan. Design: We retrospectively analyzed data from our clinical trials for a total of 270 patients and compared them with the data from other studies, addressing the elderly in particular or providing subgroup information on age, to analyze the feasibility of current chemotherapy options for elderly patients and possible alternative approaches. Results: The response rates and median survival times of fit elderly patients with NSCLC who were receiving appropriate new anticancer drugs for chemotherapy, including single-agent or combination treatment, were no worse than those of younger patients, and the response rates may have been even higher in the elderly patients, while survival time was slightly poorer in this group. The risk of adverse side effects, such as myelosuppression and peripheral neuropathy, may be higher in elderly patients, who also visit the hospital more frequently. Some items on the lung cancer symptom scale for elderly patients were rated as being slightly worse than those for younger patients after chemotherapy. Conclusion: Advanced age alone should not preclude chemotherapy. New single-agent drugs, and non-platinum-based or platinum-based doublets, can all be considered as appropriate treatment for selected fit elderly patients with advanced NSCLC.",
keywords = "Elderly, Gemcitabine, Non-small cell lung cancer, Taxane, Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Shih, {Jen Fu} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2005",
month = "1",
day = "1",
doi = "10.1378/chest.128.1.132",
language = "English",
volume = "128",
pages = "132--139",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Chemotherapy for non-small cell lung cancer in elderly patients

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Shih, Jen Fu

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Study objective: To determine the appropriate chemotherapy regimen for inoperable, chemotherapy-naïve non-small cell lung cancer (NSCLC) in elderly patients. Setting: National teaching hospital in Taiwan. Design: We retrospectively analyzed data from our clinical trials for a total of 270 patients and compared them with the data from other studies, addressing the elderly in particular or providing subgroup information on age, to analyze the feasibility of current chemotherapy options for elderly patients and possible alternative approaches. Results: The response rates and median survival times of fit elderly patients with NSCLC who were receiving appropriate new anticancer drugs for chemotherapy, including single-agent or combination treatment, were no worse than those of younger patients, and the response rates may have been even higher in the elderly patients, while survival time was slightly poorer in this group. The risk of adverse side effects, such as myelosuppression and peripheral neuropathy, may be higher in elderly patients, who also visit the hospital more frequently. Some items on the lung cancer symptom scale for elderly patients were rated as being slightly worse than those for younger patients after chemotherapy. Conclusion: Advanced age alone should not preclude chemotherapy. New single-agent drugs, and non-platinum-based or platinum-based doublets, can all be considered as appropriate treatment for selected fit elderly patients with advanced NSCLC.

AB - Study objective: To determine the appropriate chemotherapy regimen for inoperable, chemotherapy-naïve non-small cell lung cancer (NSCLC) in elderly patients. Setting: National teaching hospital in Taiwan. Design: We retrospectively analyzed data from our clinical trials for a total of 270 patients and compared them with the data from other studies, addressing the elderly in particular or providing subgroup information on age, to analyze the feasibility of current chemotherapy options for elderly patients and possible alternative approaches. Results: The response rates and median survival times of fit elderly patients with NSCLC who were receiving appropriate new anticancer drugs for chemotherapy, including single-agent or combination treatment, were no worse than those of younger patients, and the response rates may have been even higher in the elderly patients, while survival time was slightly poorer in this group. The risk of adverse side effects, such as myelosuppression and peripheral neuropathy, may be higher in elderly patients, who also visit the hospital more frequently. Some items on the lung cancer symptom scale for elderly patients were rated as being slightly worse than those for younger patients after chemotherapy. Conclusion: Advanced age alone should not preclude chemotherapy. New single-agent drugs, and non-platinum-based or platinum-based doublets, can all be considered as appropriate treatment for selected fit elderly patients with advanced NSCLC.

KW - Elderly

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Taxane

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=22244460190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244460190&partnerID=8YFLogxK

U2 - 10.1378/chest.128.1.132

DO - 10.1378/chest.128.1.132

M3 - Article

VL - 128

SP - 132

EP - 139

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -